Federated Hermes Inc. Decreases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Federated Hermes Inc. decreased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% in the 4th quarter, Holdings Channel reports. The firm owned 74,207 shares of the medical research company’s stock after selling 99 shares during the quarter. Federated Hermes Inc.’s holdings in Charles River Laboratories International were worth $17,543,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. VisionPoint Advisory Group LLC increased its position in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after buying an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $37,000. Operose Advisors LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $42,000. Venturi Wealth Management LLC raised its position in Charles River Laboratories International by 74.7% during the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after acquiring an additional 112 shares during the last quarter. Finally, Provence Wealth Management Group purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at about $57,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $232.56 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The company has a market cap of $11.98 billion, a price-to-earnings ratio of 25.25, a PEG ratio of 1.78 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The firm has a 50 day moving average price of $253.87 and a 200 day moving average price of $221.91.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business’s quarterly revenue was down 7.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.98 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at $626,155.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock worth $3,693,663 over the last three months. 1.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CRL. Robert W. Baird raised their price objective on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Citigroup boosted their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Guggenheim downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. UBS Group upped their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).